YQ23 + pembrolizumab

YQ23 + pembrolizumab is an investigational combination therapy consisting of YQ23 and pembrolizumab. Pembrolizumab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), used as a checkpoint inhibitor immunotherapy. It is FDA-approved for multiple cancers as Keytruda and functions by blocking PD-1-mediated immunosuppression, enhancing immune response against tumors[1][4][6]. **YQ23** is not registered as an approved pharmaceutical product, and there is no authoritative publicly available evidence describing its mechanism, modality, or company association; thus, the combination is presumed to be investigational and unapproved, with pembrolizumab providing the established immunotherapeutic action. The intended indication, development status, and mechanism of action for YQ23 remain unclear.

Other names

MK-3475MK3475MK 3475SCH 900475SCH900475SCH-900475